ClinicalTrials.gg
CompletedNCT00244842SPIRITUpdated Mar 27, 2023Results posted

Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis

A Phase 3 interventional study of voclosporin and Placebo in Psoriasis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 31 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
451
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 303 studies in Psoriasis with a site in Canada — 15 open to participants now, 32 under way, 14 of them phase 3. Psoriasis · Canada.

Enrollment
83rd of 272
451 · median 227
Started
2004
with 3 others
Phase 3
139 of 303
4 open now
Registered
10th of 303
by date

Among the 303 studies in Psoriasis with a site in Canada, this one is the 83rd largest by enrollment of the 272 interventional ones that give a count, is one of 4 that started in 2004, is one of 139 in phase 3, and was the 10th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

15 of the 303 studies in Psoriasis with a site in Canada are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 303 studies in Psoriasis with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.

Read the detailed description

Psoriasis is a chronic skin condition that can have a significant impact on patient's physical and mental well being. The most common form of psoriasis is plaque psoriasis. Targeted treatments in psoriasis have been reported recently, yet cyclosporine, a calcineurin inhibitor (CNi) remains one of the treatments which has the greatest efficacy. Voclosporin represents the possibility of a calcineurin inhibitor which is not only as efficacious as cyclosporine A, but also has an improved toxicity profile.

Comparison(s): Voclosporin at 3 dose levels (0.2, 0.3, and 0.4 mg/kg twice a day)compared to placebo.

03

Conditions studied

  • Psoriasis

Keywords

  • Randomized Controlled Trials
  • Immunosuppression
  • Adult
  • Chronic Disease
  • Dermatologic Agents
  • Female
  • Humans
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Treatment Outcome
  • Quality of Life
  • Double-Blind Method
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Plaque psoriasis ≥ 6 months prior to screening.
  • Diagnosis of stable, plaque psoriasis; i.e. psoriasis must not be spontaneously improving or worsening in the 4 weeks prior to the screening visit.
  • Plaque psoriasis involving ≥10% of the body surface area (BSA) at screening and prior to randomization at the day 0 visit.
  • PASI score ≥10 at screening and prior to randomization at the day 0 visit.
  • Not pregnant or nursing or planning to become pregnant during the course of the study.
  • Sexually active women of or less than 1 year and sexually active men who are not surgically sterile must use a reliable form of during study treatment and for at least 3 months after the last dose of study drug. Surgically sterile females are not considered to be of childbearing potential. Reliable forms of birth control include oral or depot contraceptives, and double-barrier methods.
  • Written prior to washout and screening procedures.
  • Able to keep study appointments and cooperate with all study requirements, in the opinion of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Has generalized erythrodermic, guttate, or pustular psoriasis.
  • Have other dermatoses that would interfere with the evaluation of psoriasis, at the discretion of the investigator.
  • A current or history of malignancy within 5 years or a history of lymphoma at any time. Subjects can be enrolled with a history of squamous or basal cell carcinoma that has been surgically excised or removed with curettage and electrodesiccation.
  • Has current, uncontrolled bacterial, viral, or fungal infections that require intravenous antibiotics or antifungals or had had such infections within 60 days prior to screening.
  • A history of streptococcal infection that required oral antibiotics within 30 days prior to screening.
  • A known history of tuberculosis.
  • Serologic evidence or known latent (HIV), (HBV) or (HCV) virus.
  • Uncontrolled hypertension as defined by systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥ 90 mm Hg.
  • GFR ≤ 60 ml/min.
  • Variation between the screening and Visit 1 GFR ≥30%.
  • , aspartate transaminase, or gamma-glutamyl transferase ≥ 3x (ULN).
  • White blood cell count ≤ 2.8 x 109/L.
  • Triglycerides ≥ 3x ULN.
  • Requires the following prohibited medications or treatments during the or treatment period: drugs potentiating the nephrotoxicity of voclosporin such as NSAID's or ACE inhibitors, drugs interfering with its pharmacokinetics; drugs considered to contribute to psoriasis flare; or, systemic and topical psoriasis medication (including psoralen/ultraviolet A light treatment) that may interfere with assessment of study drug efficacy.
  • Has used any drug or device within 28 days or 5 half lives (whichever is longer) prior to the screening visit.
  • Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3 months of the start of treatment. Biological agents include any virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment, or cure of diseases or injuries of man.
  • Previous exposure to voclosporin.
  • A history of clinically defined allergy to cyclosporine or any of the constituents of the voclosporin formulation (vitamin E, medium chain triglyceride oil, Tween 40, ethanol).
  • A history of alcoholism or drug addiction within 1 year prior to study entry.
  • Weighs \<45 kg (99 lbs) or > 140 kg (308 lbs).
  • A history of disease, including mental/emotional disorder that would interfere with the subject's participation in the study, or that might cause the administration of ISA247 to pose a significant risk to the subject, in the opinion of the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
451 participants (actual)

Study arms

  • Placebo comparator
    Placebo Comparator: 1

    Placebo

    Drug: Placebo

  • Active comparator
    Voclosporin 0.2 mg/kg po BID

    Voclosporin 0.2 mg/kg po BID

    Drug: voclosporin

  • Active comparator
    Voclosporin 0.3 mg/kg po BID

    Voclosporin 0.3 mg/kg po BID

    Drug: voclosporin

  • Active comparator
    Voclosporin 0.4 mg/kg po BID

    Voclosporin 0.4 mg/kg po BID

    Drug: voclosporin

Interventions

  • voclosporin 0.2, 0.3, or 0.4 mg/kg po BID

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin.

    Proportion of subjects achieving a PASI-75 at 12 weeks at each of the 3 dose levels of voclosporin.

    Time frame: Twelve Weeks

Secondary outcomes

  1. To Investigate the Safety and Tolerability of Voclosporin.

    Time frame: Twelve and twenty four weeks

  2. To Investigate the Pharmacokinetics and Pharmacodynamics of Voclosporin After Chronic Dosing in a Subset of Subjects.

    Time frame: Twelve and twenty four weeks

  3. To Evaluate the Effect of Voclosporin on Subject Quality of Life

    Time frame: Twelve and twenty four weeks

07

Results

Posted Mar 27, 2023

Participant flow

Participant flow — Overall Study
MilestonePlacebo 1ISA247 2ISA247 3ISA247 4
Started115107113116
Completed92769183
Not completed23312233

Outcome measures

PrimaryProportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin.

Proportion of subjects achieving a PASI-75 at 12 weeks at each of the 3 dose levels of voclosporin.

Time frame:
Twelve Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin.
ParticipantsPlaceboVoclosporin 0.2Voclosporin 0.3Voclosporin 0.4
Proportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin.4142644
SecondaryTo Investigate the Safety and Tolerability of Voclosporin.
Time frame:
Twelve and twenty four weeks

Results for this outcome have not been posted.

SecondaryTo Investigate the Pharmacokinetics and Pharmacodynamics of Voclosporin After Chronic Dosing in a Subset of Subjects.
Time frame:
Twelve and twenty four weeks

Results for this outcome have not been posted.

SecondaryTo Evaluate the Effect of Voclosporin on Subject Quality of Life
Time frame:
Twelve and twenty four weeks

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/115 (0.9%)4/115 (3.5%)62/115 (53.9%)
Voclosporin 0.20/107 (0%)2/107 (1.9%)67/107 (62.6%)
Voclosporin 0.31/113 (0.9%)4/113 (3.5%)65/113 (57.5%)
Voclosporin 0.40/116 (0%)1/116 (0.9%)80/116 (69%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboVoclosporin 0.2Voclosporin 0.3Voclosporin 0.4
ConvulsionNervous system disorders0/1151/1070/1130/116
Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1151/1070/1130/116
Myocardial InfarctionCardiac disorders0/1150/1071/1130/116
DyspneaRespiratory, thoracic and mediastinal disorders0/1150/1071/1130/116
Parapharyngeal AbscessInfections and infestations0/1150/1071/1130/116
Accidental DeathGeneral disorders0/1150/1071/1130/116
Bile duct cancerHepatobiliary disorders1/1150/1070/1130/116
AnxietyPsychiatric disorders1/1150/1070/1130/116
Femur fractureMusculoskeletal and connective tissue disorders1/1150/1070/1130/116
Radius fractureMusculoskeletal and connective tissue disorders1/1150/1070/1130/116
Most frequent other events
Most frequent other events
EventPlaceboVoclosporin 0.2Voclosporin 0.3Voclosporin 0.4
NasopharyngitisRespiratory, thoracic and mediastinal disorders27/11527/10734/11326/116
HeadacheNervous system disorders12/11518/10712/11326/116
Upper respiratory tract infectionInfections and infestations9/11512/10713/11312/116
DiarrhoeaGastrointestinal disorders3/1152/1074/11312/116
HypertensionVascular disorders7/1158/1078/11312/116
ArthralgiaMusculoskeletal and connective tissue disorders6/1152/1073/11311/116
VomitingGastrointestinal disorders4/1153/1072/1137/116
Blood pressure increasedVascular disorders5/1154/1075/1137/116
Glomerular Filtration Rate DecreasedInvestigations0/1150/1071/1137/116
Back painMusculoskeletal and connective tissue disorders2/1155/1076/1137/116

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboVoclosporin: 0.2Voclosporin: 0.3Voclosporin: 0.4Total
<=18 years00000
Between 18 and 65 years115107113116451
>=65 years00000
Age, Continuous
Age, Continuous(years)PlaceboVoclosporin: 0.2Voclosporin: 0.3Voclosporin: 0.4Total
Median41 (19 to 63)42 (18 to 62)40 (18 to 65)41 (18 to 65)41 (18 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVoclosporin: 0.2Voclosporin: 0.3Voclosporin: 0.4Total
Female45442535149
Male70638881302
Region of Enrollment
Region of Enrollment(participants)PlaceboVoclosporin: 0.2Voclosporin: 0.3Voclosporin: 0.4Total
Canada115107113116451
08

Study locations

31 sites
  • Isotechnika Investigational Site
    Calgary, Alberta T2S 3B3, Canada
  • Isotechnika Investigational Site'
    Edmonton, Alberta T5J 3S9, Canada
  • Isotechnika Investigational Site
    Edmonton, Alberta T5J 3S9, Canada
  • Isotechnika Investigational Site
    Vancouver, British Columbia V5Z 3Y1, Canada
  • Isotechnika Investigational Site
    Vancouver, British Columbia V5Z 4E8, Canada
  • Isotechnika Investigational Site
    Victoria, British Columbia V8R 6V4, Canada
  • Isotechnika Investigational Site
    Winnipeg, Manitoba R3C 0N2, Canada
  • Isotechnika Investigational Site
    Moncton, New Brunswick E1C 8X3, Canada
  • Isotechnika Investigational Site
    St. John's, Newfoundland and Labrador A1B 3E1, Canada
  • Isotechnika Investigational Site
    St. John's, Newfoundland and Labrador A1B 4F8, Canada
  • Isotechnika Investigational Site
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Isotechnika Investigational Site
    Hamilton, Ontario L8N 1V6, Canada
  • Isotechnika Investigational Site
    London, Ontario N5X 2P1, Canada
  • Isotechnika Investigational Site
    London, Ontario N6A 3H7, Canada
  • Isotechnika Investigational Site
    Maple, Ontario L4K 5V2, Canada
  • Isotechnika Investigational Site
    Markham, Ontario L3P 1A8, Canada
  • Isotechnika Investigational Site
    Newmarket, Ontario L3Y 6P5, Canada
  • Isotechnika Investigational Site
    North Bay, Ontario L4M 6L2, Canada
  • Isotechnika Investigational Site
    North Bay, Ontario P1B 3Z7, Canada
  • Isotechnika Investigational Site
    Oakville, Ontario L6K 1E1, Canada
  • Isotechnika Investigational Site
    Oshawa, Ontario L1H 1B9, Canada
  • Isotechnika Investigational Site
    Toronto, Ontario M5V 2T3, Canada
  • Isotechnika Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • Isotechnika Investigational Site
    Windsor, Ontario N8W 1E6, Canada
  • Isotechnika Investigational Site
    Windsor, Ontario N8W 5L7, Canada
  • Isotechnika Investigational Site
    Laval, Quebec H7G 2C0, Canada
  • Isotechnika Investigational Site
    Montreal, Quebec H2K 4L5, Canada
  • Isotechnika Investigational Site
    Montreal, Quebec H3G 1C6, Canada
  • Isotechnika Investigational Site
    Pointe Claire, Quebec H9R 4S3, Canada
  • Isotechnika Investigational Site
    Sherbrooke, Quebec J1J 2B8, Canada
  • Isotechnika Investigational Site
    Ste. Foy, Quebec G1V 4X7, Canada
09

References and documents

Publications

  • Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner A, Griffey SM, Paniagua RT, Hubble RW, Borie DC, Morris RE. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation. 2004 Sep 15;78(5):681-5. doi: 10.1097/01.tp.0000131950.75697.71. PubMed 15371668 ↗
  • Stalder M, Birsan T, Hubble RW, Paniagua RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003 Dec;22(12):1343-52. doi: 10.1016/s1053-2498(03)00033-0. PubMed 14672749 ↗
  • Abel MD, Aspeslet LJ, Freitag DG, Naicker S, Trepanier DJ, Kneteman NM, Foster RT, Yatscoff RW. ISATX247: a novel calcineurin inhibitor. J Heart Lung Transplant. 2001 Feb;20(2):161. doi: 10.1016/s1053-2498(00)00290-4. No abstract available. PubMed 11250240 ↗
  • Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, Shear NH, Huizinga RB, Maksymowych WP. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet. 2008 Apr 19;371(9621):1337-42. doi: 10.1016/S0140-6736(08)60593-0. PubMed 18424323 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2023, 17 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2005
First posted
Oct 27, 2005
Start
Dec 2004
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Results first posted
Mar 27, 2023
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00244842
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Oct 27, 2005
Start date
Dec 2004
Primary completion
Oct 2005
Completion
Oct 2005
Results posted
Mar 27, 2023
Last update
Mar 27, 2023

Study contacts

Robert Bissonnette, MD
principal investigator · Innovaderm Research
Richard Langley, MD, FRCPC
principal investigator · Eastern Canada Cutaneous Research Associates Ltd.
Gilles Lauzon, PhD MD FRCPC
principal investigator · Western Canada Dermatology Institute
Kim Papp, MD, PhD
principal investigator · Probity Medical Research
Neil Shear, MD
principal investigator · Ventana Clinical Research Organization

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion